– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant dose groups, ...

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally ad ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 (State or other ...

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.46%. A quarter ago, it was expected that this company would post a loss of $1.33 per share when it actually produced a loss of $2.53, delivering a surprise of -90.23%.Over the last four quarters, the company has surpassed ...

Exhibit 99.1 Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 an ...

Investors might want to bet on Arvinas, Inc. (ARVN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inv ...

Core Viewpoint - Arvinas, Inc. (ARVN) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook suggesting a potential impact on its near-term stock price depending on actual results compared to estimates [1] Financial Expectations - The company is expected to post a quarterly loss of $1.48 per share, reflecting a year-over-year change of +3.9% [2] - Revenues are projected to be $33.75 million, which is an increase of 3.9% from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised 43.01% higher in the last 30 days, indicating a reassessment by analysts [2] - The Most Accurate Estimate for Arvinas is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +20.71% [5] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [4] - Arvinas currently holds a Zacks Rank of 3, indicating a potential for beating the consensus EPS estimate [5][6] Historical Performance - In the last reported quarter, Arvinas was expected to post a loss of $1.33 per share but actually reported a loss of $2.53, resulting in a surprise of -90.23% [7] - Over the past four quarters, the company has beaten consensus EPS estimates two times [7] Industry Context - In comparison, Moderna (MRNA) is expected to report a loss of $3.59 per share for the same quarter, indicating a year-over-year change of -1,989.5%, with revenues expected to decline by 93.3% [9] - Moderna's consensus EPS estimate has been revised down by 17.7% in the last 30 days, and it currently has an Earnings ESP of -6.17% [9]

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Of ...

Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN).Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Details of Arvinas – Novartis agreementCopy link to sectionNovartis will pay $150 million to the pharmaceutical company up front. In return, it will secure license (exclusive) for development and commercialisation of its second-gen treatment for prostate cancer or ARV-766. The S ...

Core Insights - Arvinas has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, a second-generation PROTAC® androgen receptor degrader for prostate cancer [1][2] - The agreement includes a $150 million upfront payment and potential additional payments of up to $1.01 billion in development, regulatory, and commercial milestones, along with tiered royalties [1][2] - Novartis will handle all aspects of clinical development and commercialization for ARV-766 and the preclinical AR-V7 program [2] Group 1 - The partnership aims to accelerate the development of ARV-766 as a potential first-in-class treatment for prostate cancer patients [1][2] - ARV-766 is designed to selectively target and degrade the androgen receptor, showing preclinical activity in various tumor models, including those with AR mutations [4] - Arvinas utilizes its proprietary PROTAC® Discovery Engine platform to create therapies that degrade disease-causing proteins, with a focus on unmet medical needs [5] Group 2 - The transaction is subject to necessary consents or approvals, including antitrust considerations under the Hart-Scott-Rodino Antitrust Improvements Act [3] - Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Arvinas for this transaction [3]